Levothyroxine and pregnancy
Pro Research Analysisby 
Searched over 200M research papers
Levothyroxine and Pregnancy: A Comprehensive Review
Introduction to Levothyroxine and Pregnancy
Levothyroxine (LT4) is a synthetic form of the thyroid hormone thyroxine, commonly prescribed to manage hypothyroidism. Its role in pregnancy, particularly among women with subclinical hypothyroidism (SCH) and thyroid autoimmunity (TAI), has been extensively studied due to the potential risks these conditions pose to pregnancy outcomes.
Levothyroxine and Subclinical Hypothyroidism (SCH) in Pregnancy
Impact on Pregnancy Loss and Preterm Birth
Research indicates that LT4 supplementation can significantly reduce the risk of pregnancy loss and preterm birth in women with SCH. A meta-analysis of 13 studies involving 7970 women found that LT4 supplementation decreased the pregnancy loss rate (PLR) by 44% and the preterm birth rate (PBR) by 32% in women with SCH and/or TAI . However, the benefits were more pronounced in pregnancies achieved through assisted reproduction rather than natural conception .
Assisted Reproduction Technologies (ART)
In the context of ART, LT4 treatment has shown to improve pregnancy outcomes. A meta-analysis of randomized controlled trials (RCTs) involving 220 patients undergoing ART revealed that LT4 significantly increased the delivery rate and reduced the miscarriage rate . This suggests that LT4 supplementation is particularly beneficial for women with SCH undergoing ART.
Levothyroxine and Thyroid Autoimmunity (TAI) in Pregnancy
Effects on Pregnancy Outcomes
For women with TAI, LT4 supplementation has been associated with reduced risks of both pregnancy loss and preterm birth. A systematic review and meta-analysis found that LT4 decreased the risk of pregnancy loss by 37% and preterm birth by 32% in women with TAI . These benefits were observed in naturally conceived pregnancies but not in those achieved through assisted reproduction .
Euthyroid Women with Thyroid Peroxidase Antibodies (TPO-Ab)
The effectiveness of LT4 in euthyroid women with TPO-Ab remains controversial. A large double-blind, placebo-controlled trial involving 952 women found no significant difference in live birth rates between the LT4 and placebo groups . Similarly, another meta-analysis concluded that LT4 did not improve clinical pregnancy outcomes among euthyroid women with TPO-Ab .
Levothyroxine and Pregnancy Outcomes: A Broader Perspective
Systematic Reviews and Meta-Analyses
Several systematic reviews and meta-analyses have evaluated the impact of LT4 on pregnancy outcomes. A meta-analysis of RCTs involving 787 infertile couples undergoing IVF/ICSI found that LT4 significantly reduced the miscarriage rate but did not affect clinical pregnancy, live birth, or preterm birth rates . Another review concluded that LT4 therapy did not significantly improve pregnancy outcomes in women with positive thyroid antibodies .
Recent Diagnostic Criteria
Recent studies using updated diagnostic criteria for SCH have provided more nuanced insights. A systematic review and meta-analysis based on the 2017 American Thyroid Association criteria found that LT4 treatment reduced the risks of pregnancy loss, preterm birth, and gestational hypertension in pregnant women with SCH .
Conclusion
The use of levothyroxine in pregnancy, particularly among women with subclinical hypothyroidism and thyroid autoimmunity, shows promise in reducing adverse outcomes such as pregnancy loss and preterm birth. However, the benefits appear to be more significant in certain subgroups, such as those undergoing assisted reproduction. For euthyroid women with thyroid autoimmunity, the evidence does not strongly support the routine use of LT4. Further research, particularly large-scale RCTs, is needed to clarify these associations and optimize treatment protocols.
Sources and full results
Most relevant research papers on this topic